Otonomy ($OTIC)
Based: San Diego, CA
IPO price: $16
Close Sept. 30: $24
Change: Up 50%
Raised: $100 million

Scoop: Otonomy's IPO came amid a torrent of news for the biotech, which closed a $49 million venture round and disclosed positive late-stage results for its top prospect in a span of about three months. With that momentum, the ear specialist pulled off a top-of-its-range debut in August, and its shares have steadily risen on investor confidence in the company's commercial prospects. Otonomy's lead drug, AuriPro (OTO-201), is a sustained-release formulation of the antibiotic ciprofloxacin, designed to reduce postoperative complications in pediatric patients undergoing tube-placement surgery. The company plans to submit an FDA application next year with eyes on launching the product in 2016, all while developing a broad pipeline of treatments for disorders of the ear.

For more:
Ear disease biotech Otonomy bags $100M in a booming IPO
Fresh off Phase III success, Otonomy shoots for an $86M IPO
Otonomy pockets $49M to hit the gas on its ear treatments


Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.